Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

janssen pharmaceutica (pty) ltd - tablet - see ingredients - each tablet contains darunavir ethanolate equivalent to darunavir 400,0 mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aus nature pharmaceuticals pty ltd - lycopersicon esculentum, quantity: 250 mg (equivalent: lycopersicon esculentum, qty 2.5 g; equivalent: steroidal alkaloids calculated as solanine, qty 0.025 mg); cysteine hydrochloride, quantity: 225 mg; rosa rugosa, quantity: 18.75 mg (equivalent: rosa rugosa, qty 187.5 mg); curcuma longa, quantity: 40 mg (equivalent: curcuma longa, qty 800 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; purified water; gelatin; titanium dioxide; amaranth; brilliant blue fcf; tartrazine - may assist in lightening skin at the production level. may assist in the reduction of melanin production. may help defend existing skin against uv damage. may help to defend newly produced skin with uv barriers. may promote collagen synthesis for a more youthful and full appearance. may assist in lightening age spots may assist in lightening freckles may assist in sun protection which in turn may assist with anti ageing and photo ageing. may assist with skin whitening, lightening and evening of skin tone. may protect and boost certain biomolecules.

Yhdysvallat - englanti - NLM (National Library of Medicine)

procter & gamble pharmaceuticals - nitrofurantoin, macrocrystalline (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - capsule - 25 mg - macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of macrodantin and other antibacterial drugs, macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patient

Yhdysvallat - englanti - NLM (National Library of Medicine)

avera mckennan hospital - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 800 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

procter and gamble pharmaceuticals, inc. - nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l), nitrofurantoin, macrocrystalline (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - capsule - macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of macrobid and other antibacterial drugs, macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patients who are treated with macrobid are predisposed to persisten

Yhdysvallat - englanti - NLM (National Library of Medicine)

remedyrepack inc. - darunavir ethanolate (unii: 33o78xf0bw) (darunavir - unii:yo603y8113) - darunavir 800 mg

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

aspen-h -

Yhdysvallat - englanti - NLM (National Library of Medicine)

mylan institutional inc. - nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l), nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 75 mg - nitrofurantoin capsules, usp (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus . nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals)and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals)should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic age

Yhdysvallat - englanti - NLM (National Library of Medicine)

physicians total care, inc. - nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l), nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 75 mg - nitrofurantoin monohydrate/macrocrystals capsules are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus . nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin monohydrate/macrocrystals capsules and other antibacterial drugs, nitrofurantoin monohydrate/macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic agents appro

Yhdysvallat - englanti - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 50 mg - nitrofurantoin macrocrystals capsules are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus, and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeut